Investor profile · The Specialist
5AM Ventures
The Series-A Life Sciences Specialist With In-House Incubation
Visit websiteWhy it made the list
5AM's strategy is built around life sciences, with a core early-stage biopharmaceutical and drug-delivery focus.
Proof point
5AM's current strategy states a focus on biopharmaceuticals, drug delivery technologies and life science instruments; its 2026 news records portfolio company Latigo Biotherapeutics' upsized $345.6M IPO on Aug. 7.
Sources: 5amventures.com, 5amventures.com
- Industry focus
- Pharmaceutical; Drug Delivery; Medical Devices
- Technology focus
- Agnostic
- Stage
- Pre-seed through Series A
- Geography
- United States; Europe
- Category
- The Specialist
Team
Deborah Palestrant, PhD
Partner, Executive Chair, 4:59 Initiative
Max Farina, MD
Principal
Katie Bodner Spielberg, PhD
Principal
Is this investor a fit for you?
Assess your investment case and see which investors actually match your company.
Get Investor Ready